We serve today’s and tomorrow’s market needs by bringing biotech and specialty chemical expertise to our customers.
With more than a century of experience, we have a unique capability to connect biotech expertise with fine chemical know-how, which allows us to provide the best solutions for our customers’ success.
By continuously developing our technologies, we enable our customers to meet some of the world’s greatest challenges such as the vital need for disease prevention and treatment, clean water, abundant food, advanced materials, and enhanced hygiene and wellness.
Around the world we are driven by our firm commitment to high quality and operational excellence across the regions, functions and markets we serve, every day.
Empowerment, trust and integrity govern how we do business and how we interact with each other. As individuals and as teams, we are making this the place to go, stay and grow.
We are Lonza.
178 articles with Lonza
All investments in healthcare businesses progressing as planned to further accelerate growth
Lonza announced the adjustment of its Mid-Term Guidance 2022 to reflect the divestment of its former Water Care business unit and to emphasize Lonza's focus on growth along the Healthcare Continuum®.
Lonza announced the completion of the divestment of its former Water Care business and operations to Platinum Equity for USD 630 million.
Lonza Strengthens Pharma, Biotech and Nutrition Offerings with Aligned Structure and New Executive Committee Appointment
Lonza announced the internal alignment of its business structure to accelerate growth along the Healthcare Continuum® and strengthen the Microbial Control business.
Lonza announced that Richard Ridinger, CEO, has decided to retire from the company after seven successful years.
Lonza Achieved Another Excellent Full-Year Result in 2018 with 9% Organic Sales Growth and Strong Profitability Driven by Healthcare Businesses
Lonza reported a 9% organic sales, 12% organic CORE EBITDA and 14% organic CORE EBIT growth.
Fridtjof Helemann will leave the company on 31 March 2019, upon reaching retirement age.
Lonza Publishes IFRS 15 Adoption and Pro-Forma Numbers for Full-Year 2017 for Its Continuing Operations, Excluding Water Care Business
Lonza today is publishing unaudited Full-Year 2017 information excluding the Water Care business and taking into consideration additional reporting-related items to enable comparison and inform capital market participants about the upcoming reporting changes prior to our Full-Year 2018 results publication.
ERS Genomics Limited and Lonza Pharma & Biotech announced today a license agreement to provide Lonza with access to ERS Genomics’ CRISPR/Cas9 genome editing technology patents.
New biologics facility, scheduled to be operational in 2020, will provide development and manufacturing facilities from early- to late-clinical and early-commercial stages
Lonza Further Strengthens Focus on Its Healthcare Continuum Strategy by Signing Agreement to Divest Water Care Business to Platinum Equity
Lonza and Platinum Equity jointly announced today that Platinum Equity has entered into a definitive agreement with Lonza to acquire Lonza's Water Care business and operations for USD 630 million.
Lonza Acquires a Controlling Stake in Octane Biotech to Further Develop CocoonTM Autologous Technology
Acquisition further strengthens Lonza’s commitment to drive the next generation of manufacturing patient-specific and personalized therapies
Lonza Continues Strong Momentum in Businesses Along the Healthcare Continuum in Q3 2018 and Confirms Positive Outlook for the Full Year
Businesses in Pharma & Biotech and in Consumer Health – including capsule and combined ingredient and dosage form offerings – continued to drive growth
Lonza is holding a series of events as part of this year's Capital Markets Day from 24-26 September in Zurich and Visp (CH).
CHF 400 million investment in Lonza's biopark in Visp (CH) to expand IbexTM Solutions with two innovative offerings
CHF 400 million investment in Lonza's biopark in Visp (CH) to expand Ibex™ Solutions with two innovative offerings
Akouos, based in Boston, announced a Series A financing worth $50 million. The round was led by seed investors 5AM Ventures and New Enterprise Associates (NEA).
Lonza Bioscience is inviting visitors to explore its new dedicated website: bioscience.lonza.com.
Lonza and Innosieve Diagnostics Announce Exclusive Distribution Agreement for Rapid Bioburden Testing Technology
Lonza Pharma & Biotech and Innosieve Diagnostics announced today an exclusive distribution agreement for rapid bioburden testing technology.
Lonza announced the addition of hepatic stellate cells, Kupffer cells and liver-derived endothelial cells to its extensive hepatocytes portfolio.